Dr. Michael R. Hayden is Chief Scientific Officer at Teva Pharmaceutical Industries Ltd., a Member at American Society of Clinical Investigation, Scientific Director at Canadian Genetics Diseases Network, a Professor at University of British Columbia and Program Director at Translational Laboratory in Genetic Medicine.
He is on the Board of Directors at Xenon Pharmaceuticals, Inc., Royal Society of Canada, American Society of Human Genetics and Lycera Corp.
Dr. Hayden was previously employed as Founder by NeuroVir Therapeutic, Inc.
He also served on the board at Michael Smith Foundation for Health Research, Med BioGene, Inc., Aspreva Pharmaceuticals Corp. and Centre for Molecular Medicine & Therapeutic.
He received his undergraduate degree from the University of Cape Town and a doctorate degree from the University of Cape Town.